Filter Results:
(621)
Show Results For
- All HBS Web
(621)
- People (2)
- News (57)
- Research (447)
- Events (2)
- Multimedia (9)
- Faculty Publications (391)
Show Results For
- All HBS Web
(621)
- People (2)
- News (57)
- Research (447)
- Events (2)
- Multimedia (9)
- Faculty Publications (391)
- 11 Jun 2020
- In Practice
Are Digital Organizations Better at Overcoming COVID?
chains and people analytics to artificial intelligence-based models and automated biotechnology research, organizations further along the digital curve are responding differently than those still wondering how to evolve. The digital... View Details
Keywords: by Danielle Kost
- 10 Aug 2020
- Research & Ideas
COVID's Surprising Toll on Careers of Women Scientists
COVID-19 is claiming an unexpected career toll among scientific researchers, and particularly on women, new research shows. If you are female, have young children, or work in a lab, you are more likely to feel the career-crunching effects dealt by the pandemic,... View Details
- 28 Feb 2019
- Cold Call Podcast
Pursuing Precision Medicine at Intermountain Healthcare
- 16 Jun 2003
- Research & Ideas
Surveying the VC Landscape
public within five to seven years of its initial financing, will be able to pursue research that will not have a payoff for fifteen, twenty, or even more years in the future. (But it's not impossible—after all, venture capital has played a key role in the financing of... View Details
- 01 Jun 2022
- News
'Rooted' In Innovation
team, novel biotechnology that extends cassava’s shelf life from three days to 18 months. The process transforms the cassava tuber into nutritious food products that provide alternatives to wheat flour. The first product CassVita... View Details
Keywords: Deborah Blagg
- 02 Aug 2004
- Research & Ideas
Health Care Research and Prospects
is a lot other work at the school going on around these issues by many other faculty. For instance, Dave Scharfstein is doing great work on how capital market forces influence the development strategies of biotechnology companies. David... View Details
- 17 Nov 2003
- Research & Ideas
The Business of Babies
"The law says yes and no." Until there is more clarity, the market cannot thrive. "The best technology in the world won't help you if it's illegal," Spar said. "If advances in biotechnology are to reach their full... View Details
- 01 Nov 2024
- In Practice
Layoffs Surging in a Strong Economy? Advice for Navigating Uncertain Times
decision about entrepreneurship Starting your own company after a layoff is a significant decision. While it may seem like an opportune time, research suggests there are some important considerations. “Entrepreneurs coming from high-tech sectors such as View Details
- 01 Mar 2005
- News
A Primer on Patents
fifteen years ago, as a doctoral candidate in Harvard’s Economics Department, Lerner was collecting data on the role of VC funding in the biotechnology industry. Before long, he also became intrigued by the concept of intellectual... View Details
- 01 Mar 2003
- News
Naina Lal Kidwai
to the global automobile industry. Biotechnology and pharmaceutical firms are emerging as international players. There are also opportunities in infrastructure investment, such as telecom, ports, roads, and airports. Please comment on... View Details
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details
- February 1986 (Revised November 1992)
- Case
Novo Industri A/S--1981
By: W. Carl Kester and Glynn Ferguson
This small but rapidly growing Danish biochemical company must choose among several financing opportunities that include a convertible Eurobond, a rights offering in Denmark and an issue of new common shares in the United States. The case involves a broad range of... View Details
Keywords: Capital Markets; Cost of Capital; Bonds; Stock Shares; Financing and Loans; Globalization; Biotechnology Industry; Biotechnology Industry; Denmark; United States
Kester, W. Carl, and Glynn Ferguson. "Novo Industri A/S--1981." Harvard Business School Case 286-084, February 1986. (Revised November 1992.)
- March 2022
- Teaching Note
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This teaching note provides guidance for instructors teaching “Digital Manufacturing at Amgen,” case no. 621-008. View Details
Keywords: Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information Technology; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Technology Adoption; Biotechnology Industry; Biotechnology Industry; United States; California; Puerto Rico; Rhode Island
- November 2020
- Supplement
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
- October 2019 (Revised April 2020)
- Background Note
Note on Funding Deep Tech Startups
By: Karim Lakhani, Peter Barrett and Noubar Afeyan
This Background Note provides essential information on funding deep technologies—those technologies that were inherently capital intensive, time consuming, risky, and potentially disruptive. Both dilutive and non-dilutive sources of investment are highlighted, along... View Details
Keywords: Entrepreneurship; Energy; Venture Capital; Corporate Finance; Initial Public Offering; Investment; Health Testing and Trials; Innovation and Invention; Technological Innovation; Intellectual Property; Product Design; Product Development; Information Technology; Research and Development; Risk and Uncertainty; Biotechnology Industry; Biotechnology Industry; United States; North America; Europe; Asia
Lakhani, Karim, Peter Barrett, and Noubar Afeyan. "Note on Funding Deep Tech Startups." Harvard Business School Background Note 620-029, October 2019. (Revised April 2020.)
- September 2019
- Case
Celgene: Business Development and Distributed Research
By: Peter Barrett and Kareem Reda
This case looks at the deal-making process between Celgene, a large publicly traded pharmaceutical company, and Agios, an early-stage biotech company. The framework of a potential deal is explored and the potential road-blocks to Agios’ profitability are discussed. ... View Details
Keywords: Negotiation Deal; Alliances; Collaborative Innovation and Invention; Research; Biotechnology Industry; Biotechnology Industry
Barrett, Peter, and Kareem Reda. "Celgene: Business Development and Distributed Research." Harvard Business School Case 620-014, September 2019.
- June 2014
- Supplement
Merrimack Pharmaceuticals, Inc. (B)
By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine
In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details
Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Biotechnology Industry; Biotechnology Industry
Edmondson, Amy C., Bethany Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 614-083, June 2014.
- April 2010
- Teaching Note
The DiagnoFirst Opportunity (TN)
By: Robert C. Pozen
Teaching Note for [309112]. View Details
- February 2010 (Revised April 2010)
- Case
Organization and Strategy at Millennium (A)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details
Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Biotechnology Industry; Biotechnology Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (A)." Harvard Business School Case 710-415, February 2010. (Revised April 2010.)
- January 2009
- Teaching Note
Biocon: Launching a New Cancer Drug in India (TN)
By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details